What it is claimed to help
These are the uses attached to Tesamorelin in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Approved by the FDA with randomised human trial data behind the label.
Real and randomised, within its lane. Pivotal trials showed roughly 15-18% reduction in visceral adipose tissue in HIV-associated lipodystrophy. A separate NIH randomised trial reported reduced liver fat and less fibrosis progression in people with HIV and NAFLD. Outside HIV populations the evidence is thin, and it is widely used off-label on that basis.
How it is supposed to work
Stabilised growth-hormone-releasing hormone analogue: stimulates pulsatile endogenous GH release rather than replacing GH directly.
Safety
Arthralgia, injection site reactions, oedema, and glucose intolerance. Contraindicated in active malignancy. Requires an intact pituitary.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- FDA prescribing information, Egrifta
- Falutz J et al. Tesamorelin pivotal trials, NEJM 2007
- Stanley TL et al. Tesamorelin and liver fat in HIV, Lancet HIV 2019
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.